Zentalis Pharmaceuticals Inc
Fermé
4.05 -0.98
Résumé
Variation du prix de l'action
24h
Min
4.03
Max
4.05
Revenu | -136K -35M |
|---|---|
Employés | 106 |
EBITDA | -619K -38M |
Recommandations | Achat |
|---|---|
Prévisions sur 12 Mois | +72.41% upside |
Prochains Résultats | 4 août 2026 |
|---|
Capitalisation Boursière | -36M 258M |
|---|---|
Ouverture précédente | 5.03 |
Clôture précédente | 4.05 |
Zentalis Pharmaceuticals Inc Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
Actualités Associées
Comparaison
Variation de prix
Zentalis Pharmaceuticals Inc prévision
Objectif de Prix
By TipRanks
72.41% hausse
Prévisions sur 12 Mois
Moyen 7 USD 72.41%
Haut 10 USD
Bas 4 USD
Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.
Éléments financiers
Frais Généraux et Administratifs
Dépenses d'exploitation
Résultat avant impôt
Ventes
Coût des ventes
Marge brute des ventes
Charges d'intérêt sur la dette
EBITDA
Bénéfice d'exploitation
$
À Propos Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
